Multidisciplinary management of pyogenic spondylodiscitis: epidemiological and clinical features, prognostic factors and long-term outcomes in 207 patients
Pyogenic spondylodiscitis (PS) is a potentially life-threatening infection burdened by high morbidity rates. Despite the rising incidence, the proper management of PS is still controversial. Aim of this study was to describe the clinical features of PS and to evaluate the prognostic factors and the long-term outcomes of a large population of patients.
207 cases of PS treated from 2008 to 2016 with a 2-year follow-up were enrolled. Clinical data from each patient were recorded. The primary outcome was the rate of healing without residual disability. Secondary outcomes included length of stay, healing from infection, death, relapse, and residual disability. Binomial logistic regression and multivariate analysis were used to evaluate prognostic factors.
Median diagnostic delay was 30 days and the rate of onset neurological impairment was 23.6%. Microbiological diagnosis was established in 155 patients (74.3%) and the median duration of total antibiotic therapy was 148 days. Orthopedic treatment was conservative for 124 patients and surgical in 47 cases. Complete healing without disability was achieved in 142 patients (77.6%). Statistically confirmed negative prognostic factors were: negative microbiological culture, neurologic impairment at diagnosis and underlying endocarditis (p ≤ 0.05). Healing from infection rate was 90.9%, while residual disabilities occurred in 23.5%. Observed mortality rate was 7.8%.
The microbiological diagnosis is the main predictive factor for successful treatment. Early diagnosis and multidisciplinary management are also needed to identify underlying aggressive conditions and to avoid neurological complications associated with poorer long-term outcomes. Despite high healing rates, PS may lead to major disabilities still representing a difficult challenge.
KeywordsSpondylodiscitis Prognostic factors Outcomes Antibiotic therapy Orthopedic treatment
The authors declare that they received no grants or funding.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 6.Krogsgaard MR, Wagn P, Bengtsson J (1998) Epidemiology of acute vertebral osteomyelitis in Denmark: 137 cases in Denmark 1978–1982, compared to cases reported to the National Patient Register 1991–1993. Acta Orthop Scand 69:513–517. https://doi.org/10.3109/17453679808997789 CrossRefPubMedGoogle Scholar
- 8.Akiyama T, Chikuda H, Yasunaga H, Horiguchi H, Fushimi K, Saita K (2013) Incidence and risk factors for mortality of vertebral osteomyelitis: a retrospective analysis using the Japanese diagnosis procedure combination database. BMJ Open 3:e002412. https://doi.org/10.1136/bmjopen-2012-002412 CrossRefPubMedPubMedCentralGoogle Scholar
- 9.Lora-Tamayo J, Euba G, Narváez JA, Murillo O, Verdaguer R, Sobrino B, Narváez J, Nolla JM, Ariza J (2011) Changing trends in the epidemiology of pyogenic vertebral osteomyelitis: the impact of cases with no microbiologic diagnosis. Semin Arthritis Rheum 41:247–255. https://doi.org/10.1016/j.semarthrit.2011.04.002 CrossRefPubMedGoogle Scholar
- 13.Berbari EF, Kanj SS, Kowalski TJ, Darouiche RO, Widmer AF, Schmitt SK, Hendershot EF, Holtom PD, Huddleston PM 3rd, Petermann GW, Osmon DR (2015) Infectious Diseases Society of America. 2015 Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for the Diagnosis and Treatment of Native Vertebral Osteomyelitis in Adults. Clin Infect Dis 61:e26–e46. https://doi.org/10.1093/cid/civ482 CrossRefPubMedGoogle Scholar
- 14.Pola E, Autore G, Formica VM, Pambianco V, Colangelo D, Cauda R, Fantoni M (2017) New classification for the treatment of pyogenic spondylodiscitis: validation study on a population of 250 patients with a follow-up of 2 years. Eur Spine J 26(Suppl 4):479–488. https://doi.org/10.1007/s00586-017-5043-5 CrossRefPubMedGoogle Scholar
- 18.Lee IS, Lee JS, Kim SJ, Jun S, Suh KT (2009) Fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography imaging in pyogenic and tuberculous spondylitis: preliminary study. J Comput Assist Tomogr 33:587–592. https://doi.org/10.1097/RCT.0b013e318187fef8 CrossRefPubMedGoogle Scholar
- 19.Bernard L, Dinh A, Ghout I, Simo D, Zeller V, Issartel B, Le Moing V, Belmatoug N, Lesprit P, Bru JP, Therby A, Bouhour D, Dénes E, Debard A, Chirouze C, Fèvre K, Dupon M, Aegerter P, Mulleman D (2015) Duration of Treatment for Spondylodiscitis (DTS) study group (2015) Antibiotic treatment for 6 weeks versus 12 weeks in patients with pyogenic vertebral osteomyelitis: an open-label, non-inferiority, randomised, controlled trial. Lancet 385:875–882. https://doi.org/10.1016/S0140-6736(14)61233-2 CrossRefPubMedGoogle Scholar
- 20.Park KH, Cho OH, Lee JH, Park JS, Ryu KN, Park SY, Lee YM, Chong YP, Kim SH, Lee SO, Choi SH, Bae IG, Kim YS, Woo JH, Lee MS (2016) Optimal duration of antibiotic therapy in patients with hematogenous vertebral osteomyelitis at low risk and high risk of recurrence. Clin Infect Dis 62:1262–1269. https://doi.org/10.1093/cid/ciw098 CrossRefPubMedGoogle Scholar
- 23.Pola E, Logroscino CA, Gentiempo M, Colangelo D, Mazzotta V, Di Meco E, Fantoni M (2014) Medical and surgical treatment of pyogenic spondylodiscitis. Eur Rev Med Pharmacol Sci 16(Suppl 2):35–49Google Scholar
- 24.Nasto LA, Colangelo D, Mazzotta V, Di Meco E, Neri V, Nasto RA, Fantoni M, Pola E (2014) Is posterior percutaneous screw-rod instrumentation a safe and effective alternative approach to TLSO rigid bracing for single-level pyogenic spondylodiscitis? Results of a retrospective cohort analysis. Spine J 14:1139–1146. https://doi.org/10.1016/j.spinee.2013.07.479 CrossRefPubMedGoogle Scholar